Molecular Partners Ag

Ivo Sonderegger

Hans Kaspar Binz

Daniel Steiner

Douglas Phillips

Frieder W Merz

Maya Gulotti-Georgieva

Patrik Forrer

Michael Tobias Stumpp

Ignacio Dolado

Talitha Bakker

Johan Abram Saliba

Michael T Stumpp

New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.

Recombinant binding proteins and their use

New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin.

Designed repeat proteins binding to serum albumin

Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains

Growing community of inventors

Urdorf, Switzerland

Ivo Sonderegger